Literature DB >> 31352662

Resveratrol for High Blood Pressure: A Total Failure or the Need to Identify the Right Patient?

Federica Fogacci1, Silvia Fogacci2, Arrigo Cicero2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31352662     DOI： 10.1007/s40292-019-00333-5

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN： 1120-9879


× No keyword cloud information.
  20 in total

1.  ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia.

Authors: 
Journal:  Obstet Gynecol       Date:  2019-01       Impact factor: 7.661

Review 2.  Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach.

Authors:  Arrigo F G Cicero; Federica Fogacci; Alessandro Colletti
Journal:  Food Funct       Date:  2017-06-21       Impact factor: 5.396

Review 3.  Therapeutic potential of resveratrol: the in vivo evidence.

Authors:  Joseph A Baur; David A Sinclair
Journal:  Nat Rev Drug Discov       Date:  2006-05-26       Impact factor: 84.694

4.  Resveratrol effect on patients with non-alcoholic fatty liver disease: A matter of dose and treatment length.

Authors:  Federica Fogacci; Maciej Banach; Arrigo Francesco Giuseppe Cicero
Journal:  Diabetes Obes Metab       Date:  2018-05-02       Impact factor: 6.577

Review 5.  Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials.

Authors:  Kannan Sridharan; Reginald P Sequeira
Journal:  Br J Clin Pharmacol       Date:  2018-07-08       Impact factor: 4.335

6.  The Effects of Resveratrol Supplementation on Endothelial Function and Blood Pressures Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Maryam Akbari; Omid Reza Tamtaji; Kamran B Lankarani; Reza Tabrizi; Ehsan Dadgostar; Fariba Kolahdooz; Mehri Jamilian; Hamed Mirzaei; Zatollah Asemi
Journal:  High Blood Press Cardiovasc Prev       Date:  2019-07-01

7.  Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy.

Authors:  Martina Montagnana; Giuseppe Lippi; Alessandro Albiero; Silvia Scevarolli; Gian Luca Salvagno; Massimo Franchi; Gian Cesare Guidi
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

8.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.

Authors:  Harald Zeisler; Elisa Llurba; Frederic Chantraine; Manu Vatish; Anne Cathrine Staff; Maria Sennström; Matts Olovsson; Shaun P Brennecke; Holger Stepan; Deirdre Allegranza; Peter Dilba; Maria Schoedl; Martin Hund; Stefan Verlohren
Journal:  N Engl J Med       Date:  2016-01-07       Impact factor: 91.245

9.  Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs.

Authors:  J Chen; Q Bai; Z Zhao; H Sui; X Xie
Journal:  Acta Neurol Scand       Date:  2015-10-12       Impact factor: 3.209

10.  Efficacy of resveratrol to supplement oral nifedipine treatment in pregnancy-induced preeclampsia.

Authors:  Jian Ding; Yan Kang; Yuqin Fan; Qi Chen
Journal:  Endocr Connect       Date:  2017-11       Impact factor: 3.335
View more
  3 in total

Review 1.  The Potential of Resveratrol to Act as a Caloric Restriction Mimetic Appears to Be Limited: Insights from Studies in Mice.

Authors:  Kathrin Pallauf; Ilka Günther; Gianna Kühn; Dawn Chin; Sonia de Pascual-Teresa; Gerald Rimbach
Journal:  Adv Nutr       Date:  2021-06-01       Impact factor: 8.701

2.  Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors comparing subjects with metabolic syndrome and healthy subjects with or without obesity: meta-analysis using multinational, randomised, controlled trials.

Authors:  Consolato Sergi; Bonnie Chiu; Joseph Feulefack; Fan Shen; Brian Chiu
Journal:  Arch Med Sci Atheroscler Dis       Date:  2020-05-30

3.  Towards resolving the enigma of the dichotomy of resveratrol: cis- and trans-resveratrol have opposite effects on TyrRS-regulated PARP1 activation.

Authors:  Megha Jhanji; Chintada Nageswara Rao; Mathew Sajish
Journal:  Geroscience       Date:  2020-11-27       Impact factor: 7.713
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.